Management of hypertension in elderly diabetic patients

Diabetes and Metabolism

Volumn 31, Issue SPEC. ISS. 2, 2005, Pages

  Blickle J F ^a,b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

Anti hypertensive drugs; Diabetes; Elderly subject; Hypertension

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; VERAPAMIL;

AGING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPERTENSION; KIDNEY DISEASE; REVIEW;

EID: 30844464153     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(05)73656-9     Document Type: Review

References (43)

1. European Diabetes Working Party for older people 2001-2004. Clinical Guidelines for type 2 diabetes mellitus. May 2004. www.eugms.org/academic/ guidelines
2. Miyagi T, Muratani H, Kimura Y, et al. Increase in pulse pressure relates to diabetes mellitus and low HDL cholesterol, but not to hyperlipidemia in hypertensive patients aged 50 years or older. Hypertens Res 2002;25:335-41.
3. Mulrow C, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2000;2:CD000028.
4. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999;353:793-6.
5. Curb JD, Pressel SL, Cutler JA, et al. Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diureticbased antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92. Erratum, JAMA 1997;277:1356.
6. Kostis JB, Wilson AC, Freudenberger RS, et al. SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35.
7. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.
8. Staessen JA, Thijisq L, Fagard R, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004;22:847-57.
9. Bulpitt CJ, Beckett NS, Cooke J, et al. Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003;21:2409-17.
10. Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
11. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53 [Erratum, N Engl J Med 2000;342:748&1376].
13. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
14. Ogihara T, Saruta T, Matsuoka H, et al. Valsartan in elderly isolated systolic hypertension (VALISH) study: rationale and design. Hypertens Res 2004;27:657-61.
15. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996;276:785-91.
16. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72. Erratum, Lancet 2000;356:514.
17. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004;164:2459-64.
18. Black HR, Elliott WJ, Grandits G, et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 2003;289:2073-82.
19. Kjeldsen SE, Hedner T, Syvertsen JO, et al. NORDIL Study Group. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hypertens 2002;20:1231-7.
20. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18:1671-5.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288,2981-97.
22. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
23. Lindholm LH, Ibsen H, Dahlöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
24. Devereux RB, Dahlöf B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110 :1456-62.
25. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998,338, 645-52.
26. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
27. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
28. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
29. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
30. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358,1033-41.
31. Mogensen CE, Neldam S, Tikkanen I, et al. CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
32. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
33. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
34. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
35. Mallion JM, Genès N, Vaur L, et al. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. J Hum Hypertens 2001;15:841-8.
36. AFSSAPS. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle - Actualisation 2005. Texte des recommandations. Version finale du 6.6.2005. www.afssaps.sante.fr
37. Omvik P, Gerhardsen G. The Norwegian office-, home-, and ambulatory blood pressure study (NOHA). Blood Press 2003;12:211-9.
38. Rubio Guerra A, Rodriguez Lopez L, Vargas Ayala G, Narvaez Rivera JL, Lozano Nuevo JJ. Prevalence of white-coat hypertension in a geriatric population with a diagnosis of isolated systolic hypertension. Rev Esp Cardiol 2001;54:1116-8.
39. Mallion JM, Genès N, Vaur L, et al. Detection of masked hypertension by home blood pressure measurement: is the number of measurements an important issue? Blood Press Monit 2004;9:301-5.
40. Mazze RS, Robinson R, Simonson G, et al. Undetected, uncontrolled blood pressure in type 2 diabetes: self-monitored blood pressure profiles. Blood Press 2004;13:335-42.
41. Goss DE, Stevens M, Watkins PJ, Baskerville PA. Falsely raised ankle/brachial pressure index: a method to determine tibial artery compressibility. Eur J Vasc Surg 1991;5:23-6.
42. Foran TG, Sheahan NF, Cunningham C, Feely J. Pseudo-hypertension and arterial stiffnes: a review. Physiol Meas 2004;25:R21-R33.
43. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Amer Geriatr Soc 2003;51:S265-S280.